---
title: 'Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy
  Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes
  Survey (THAOS)'
date: '2024-06-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38909877/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240624182446&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: In this real-world cohort of patients with ATTR-CM, survival
  rates were higher than in ATTR-ACT and consistent with more recent reports, suggesting
  early diagnosis and treatment with tafamidis has improved life expectancy in ATTR-CM.
  These results provide further evidence supporting tafamidis'' safety and ...'
disable_comments: true
---
CONCLUSIONS: In this real-world cohort of patients with ATTR-CM, survival rates were higher than in ATTR-ACT and consistent with more recent reports, suggesting early diagnosis and treatment with tafamidis has improved life expectancy in ATTR-CM. These results provide further evidence supporting tafamidis' safety and ...